Content area
Full Text
Science Exchange’s outsourced R&D platform has already been used by biopharma big names such as GlaxoSmithKline, Merck, Bristol-Myers Squibb and Roche; and now, through an agreement with biotech accelerator IndieBio, the company is offering the same services to some startups.
The partnership will give IndieBio-backed startups access to Science Exchange’s network of more than 2,500 R&D service providers, which includes renowned research institutions and major CROs like Covance, Charles River and WuXi AppTec. This will potentially help “level the playing field” for these fledgling companies with established industry leaders, said Science Exchange in a release.
To sweeten...